

## Curcumin Potentiates the Potent Antitumor Activity of ACNU Against Glioblastoma by Suppressing the PI3K/AKT and NF- $\kappa$ B/COX-2 Signaling Pathways [Retraction]

Zhao J, Zhu J, Lv X, et al. *Onco Targets Ther.* 2017;10:5471–5482.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 3C. Specifically,

- Figure 3C, DMSO appears to have been duplicated with the same image for Figure 3C, ACNU.

The authors responded to our queries and explained that the image duplication in Figure 3 was due to image misplacement during preparation of the figure. The authors were asked to provide original data that would adequately verify the reported findings, however the authors explained that some of the original data had been lost and the remaining data was not satisfactory. The Editor determined that the reported findings were unreliable and requested to retract the article. The authors agreed with this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>